Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12859116 | 0.95 | MAPK1 (0.37) | MAPK1ALDH1A1MAPTCASP3BLM | |
| SCHEMBL12863317 | 0.93 | MAPK1 (0.36) | MAPK1ALDH1A1 | |
| SCHEMBL20128733 | 0.87 | MAPK1 (0.32) | MAPK1ALDH1A1 | |
| SCHEMBL13166789 | 0.86 | — | — | |
| SCHEMBL11947205 | 0.84 | MAPK1 (0.40) | MAPK1 | |
| SCHEMBL24084013 | 0.81 | MAPT (0.32) | MAPK1ALDH1A1MAPTCASP3BLM | |
| SCHEMBL19655525 | 0.81 | MAPT (0.32) | MAPK1ALDH1A1MAPTCASP3BLM | |
| SCHEMBL10717480 | 0.81 | MAPK1 (0.36) | MAPK1ALDH1A1TDP1 | |
| SCHEMBL2735121 | 0.81 | ALDH1A1 (0.41) | MAPK1ALDH1A1MAPTCASP3BLM | |
| SCHEMBL21421559 | 0.80 | HRH2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| US-7732413-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080234248-A1 | Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof | SCHERING CORPORATION (US) | 2008-09-25 | — | — | US | disclosed |
| US-7378518-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-05-27 | — | — | US | disclosed |
| US-7368562-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155674-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BCL2A1, BAX, BCL2 | MAPK1 3160/4885ALDH1A1 3017/4885MAPT 4846/4885 |
| US-20070155674-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | MAPK1 3541/4885ALDH1A1 2497/4885MAPT 3020/4885 |
| US-20080234248-A1 | Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof | CYP46A1, NPC1L1, PCSK9 | MAPK1 3088/4885ALDH1A1 1219/4885MAPT 3296/4885 |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | MAPK1 3552/4885ALDH1A1 3814/4885MAPT 4858/4885 |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | MAPK1 3541/4885ALDH1A1 2497/4885MAPT 3020/4885 |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | MAPK1 3552/4885ALDH1A1 3814/4885MAPT 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.